Patents by Inventor Gregory Sieczkiewicz

Gregory Sieczkiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammalian cells and methods for engineering the same
    Patent number: 12241062
    Abstract: The present disclosure provides mammalian cell lines for expression of viral vectors, and methods of making and using the same. Provided methods employ use of identifiers that are capable of being packaged into a viral vector to select and/or identify mammalian cell lines with engineered sequences associated with beneficial characteristics for viral vectors production. Exemplary viral vectors include AAV vectors.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: March 4, 2025
    Assignee: 64-X, Inc.
    Inventors: Alexis Rovner, Gaurab Chakrabarti, David Thompson, Gregory Sieczkiewicz
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20240301026
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs). T-cells engineered to express one or more TFPs. and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: March 8, 2024
    Publication date: September 12, 2024
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11965012
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: April 23, 2024
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAME
    Publication number: 20240076655
    Abstract: The present disclosure provides mammalian cell lines for expression of viral vectors, and methods of making and using the same. Provided methods employ use of identifiers that are capable of being packaged into a viral vector to select and/or identify mammalian cell lines with engineered sequences associated with beneficial characteristics for viral vectors production. Exemplary viral vectors include AAV vectors.
    Type: Application
    Filed: October 23, 2023
    Publication date: March 7, 2024
    Inventors: Alexis Rovner, Gaurab Chakrabarti, David Thompson, Gregory Sieczkiewicz, McKenna Hicks, Joseph Bellucci
  • MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAME
    Publication number: 20240052341
    Abstract: The present disclosure provides mammalian cell lines for expression of viral vectors, and methods of making and using the same. Provided methods employ use of identifiers that are capable of being packaged into a viral vector to select and/or identify mammalian cell lines with engineered sequences associated with beneficial characteristics for viral vectors production. Exemplary viral vectors include AAV vectors.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 15, 2024
    Inventors: Alexis Rovner, Gaurab Chakrabarti, David Thompson, Gregory Sieczkiewicz, McKenna Hicks, Joseph Bellucci
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20230235010
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 27, 2023
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20220298478
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 22, 2022
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11377638
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 5, 2022
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11242376
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: February 8, 2022
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210206827
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 8, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11028142
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: June 8, 2021
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210079057
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 13, 2018
    Publication date: March 18, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20200362306
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 19, 2020
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20200362011
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 19, 2020
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20200207828
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 2, 2020
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10442849
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 15, 2019
    Assignee: TCR2 THERABEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20190256571
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 2, 2017
    Publication date: August 22, 2019
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10358473
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 23, 2019
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10358474
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 23, 2019
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister